An interventional study of Angiography and Optical Coherence Tomography evaluations in Coronary Artery Disease, sponsored by Scitech Produtos Medicos Ltda. Completed at 5 sites in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-09-04.
Sponsored by Scitech Produtos Medicos Ltda · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 30 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 77th largest by enrollment of the 123 interventional ones that give a count, is one of 11 that started in 2017, is one of 67 with no phase, and was the 88th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:
Scitech Produtos Medicos SA · Sites in Brazil
Ages 18+
InCor Heart Institute · Sites in Brazil
Ages 45–70 · Women only
University of Sao Paulo General Hospital · Sites in Brazil
Ages 46–69 · Men only
Instituto Nacional de Cardiologia de Laranjeiras · Sites in Brazil
Ages 40–70 · Healthy volunteers
University of Sao Paulo General Hospital · Sites in Brazil
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 25 · Phase 4 17
First in 1999; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 123 interventional studies, 740 across the 28 observational. Of the 92 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 152 have an industry lead sponsor. The 10 most frequent:
Scitech Produtos Medicos Ltda is the lead sponsor of 13 studies on the registry; none are open to participants now.
Scitech Produtos Medicos Ltda has 9 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Artery Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579807Instituto Nacional de Cardiologia de LaranjeirasCardiac Rehabilitation and Coronary Artery Disease | 2026-12-31 |
| NCT07699679Federal University of São PauloPhotobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting. | 2027-08 |
| NCT07734831University of the State of Santa CatarinaTELEREHAB-BR: Cardiovascular Rehabilitation Models Trial | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multicentric, single-arm study to evaluate fast and effective tissue repair in patients undergone percutaneous coronary intervention with drug eluting stent Inspiron.
The first 20 patients enrolled will be evaluated by angiography and Optical Coherence Tomography 3 months after stent implantation. The following 20 patients will be evaluated by the same methods 2 months after the implantation and the last 20 patients after 30 days.
All patients will be clinically followed at 30 days, 6 months, 1 and 2 years after index procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Angiography and Optical Coherence Tomography evaluations
Device: Angiography and Optical Coherence Tomography evaluations
Angiography and Optical Coherence Tomography evaluations
Device: Angiography and Optical Coherence Tomography evaluations
Angiography and Optical Coherence Tomography evaluations
Device: Angiography and Optical Coherence Tomography evaluations
coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
Tissue Coverage
Change in the tissue coverage percentage measured by OCT
Time frame: 3 months
in-stent late lumen loss
in-stent late lumen loss
Time frame: 3 months
Stent Thrombosis
Stent Thrombosis Rates
Time frame: 2 years
Target Vessel Failure
Target Vessel Failure (Death, MI and new revascularization)
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Dec 2018, 14 months.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 14 months is below that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scitech Produtos Medicos Ltda